Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» 3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started
3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started
3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started
Submitted by
admin
on August 3, 2021 - 11:03am
Source:
Motley Fool
News Tags:
Pfizer
Moderna Therapeutics
vaccines
COVID-19
Headline:
3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started
snippet:
Pfizer’s and Moderna’s safety and efficacy profiles give them an advantage over rivals.
One potential audience may not boost orders and revenue today -- but may do so in a major way down the road.
Do Not Allow Advertisers to Use My Personal information
